Apixaban Dosing for Atrial Fibrillation
The standard dose of apixaban for adults with non-valvular atrial fibrillation is 5 mg orally twice daily, with dose reduction to 2.5 mg twice daily required when patients meet at least 2 of the following 3 criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1
Standard Dosing Algorithm
Start with 5 mg twice daily for most patients with non-valvular atrial fibrillation. This is the FDA-approved standard dose that demonstrated superior efficacy to warfarin in the ARISTOTLE trial, with significantly lower rates of major bleeding (2.13%/year vs 3.09%/year) and intracranial hemorrhage (0.24%/year vs 0.47%/year). 2
Dose Reduction Criteria
Reduce to 2.5 mg twice daily ONLY when the patient has ≥2 of these characteristics:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
This is a strict "at least 2 out of 3" rule. Having only one criterion does NOT warrant dose reduction. The reduced dose was specifically tested in both the ARISTOTLE and AVERROES trials using these exact criteria. 2
Critical Dosing Pitfalls
Inappropriate dose reduction is extremely common in clinical practice and must be avoided. Real-world data shows that approximately 60% of patients receiving reduced-dose apixaban do not actually meet the labeling criteria for dose reduction. 4, 5, 6 This inappropriate underdosing is associated with significantly higher mortality (adjusted HR: 1.77) without clear reductions in bleeding risk. 5
The most common error is reducing the dose based on a single criterion (typically age alone or renal function alone) rather than requiring at least 2 criteria. 6, 7 Clinicians must resist the temptation to empirically reduce doses in elderly patients or those with mild renal impairment if they don't meet the 2-out-of-3 threshold.
Special Populations
For patients with end-stage renal disease on hemodialysis: Use 5 mg twice daily as the standard dose, reducing to 2.5 mg twice daily only if the patient is also ≥80 years old OR weighs ≤60 kg (not requiring both). 8, 9
For patients with creatinine clearance 15-50 mL/min: No automatic dose adjustment is required for apixaban unless the patient also meets the other dose-reduction criteria (age ≥80 or weight ≤60 kg). This differs from rivaroxaban and dabigatran, which require dose adjustment based on renal function alone. 9, 8, 9, 10
Evidence Supporting This Approach
The ARISTOTLE trial enrolled 18,201 patients and demonstrated that apixaban 5 mg twice daily (with 2.5 mg twice daily in those meeting dose-reduction criteria) was superior to warfarin for preventing stroke/systemic embolism (HR 0.79,95% CI 0.66-0.95, P=0.01 for superiority) while causing significantly less major bleeding. 2 The dose-reduction strategy used in this trial forms the basis for current FDA labeling. 1
Importantly, subgroup analyses confirmed consistent efficacy and safety of apixaban across patients with impaired renal function (eGFR <80 mL/min), with even greater bleeding reduction in those with more advanced renal dysfunction (eGFR ≤50 mL/min). 2 This supports the safety of standard dosing in moderate renal impairment when other dose-reduction criteria are not met.
Practical Implementation
- Calculate all three parameters before prescribing: exact age, actual body weight, and serum creatinine level
- Count how many criteria are met (must be ≥2 for dose reduction)
- Prescribe 5 mg twice daily if 0-1 criteria are met
- Prescribe 2.5 mg twice daily if ≥2 criteria are met
- Reassess periodically as weight and renal function can change over time
The evidence strongly supports adherence to these specific FDA-approved criteria rather than empiric dose adjustments based on clinical judgment alone. 3, 1